Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




Omalizumab Not Cost Effective for Severe Asthma
Link ID 1733
Title Omalizumab Not Cost Effective for Severe Asthma
Url http://www.medscape.com/viewarticle/567546?src=rss
Description Omalizumab is not a cost-effective treatment for most patients with severe asthma, according to an analysis presented in the November Journal of Allergy and Clinical Immunology. Reuters Health Information
Category Articles > Allergy and Clinical Immunology
Keywords
Date Dec 20, 2007
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Allergy and Clinical Immunology
1. NY Course 2008: HIV Pathogenesis and Prevention
  Drs. Lederman and Herold review HIV pathogenesis and continuing efforts to develop an effective microbicide against HIV infection in their talks from HIV Management 2008: The New York Course. Medscape HIV/AIDS
Category:   Articles > Allergy and Clinical Immunology


2. Neonatal Screening for Severe Combined Immune Deficiency
  An update on the latest developments in newborn screening for severe combined immunodeficiency.
Current Opinion in Allergy and Clinical Immunology
Category:   Articles > Allergy and Clinical Immunology


3. Risk for Second Nonlymphoid Neoplasms in Chronic Lymphocytic Leukemia
  Improvements in selection of chemotherapeutic and/or immunotherapeutic regimens will hopefully reduce long-term complications and will allow their curative potential to be utilized.
Medscape General Medicine
Category:   Articles > Allergy and Clinical Immunology


4. A New Dawn in Cardio and Vascular Protection V. Cardiovascular High-Risk Patients: Treat to Protect
  This article introduces a 6-article supplement that was presented at an international symposium held in Madrid, Spain, on May 4-5, 2007, sponsored by Boehringer Ingelheim.
The Medscape Journal of Medicine
Category:   Articles > Allergy and Clinical Immunology


5. Rituximab Reduces Brain Lesions, Clinical Relapses in RRMS
  Results of a phase 2 trial show a single course of rituximab reduced both lesions on MRI and clinical relapses in relapsing-remitting multiple sclerosis. The results support the concept of B-cell involvement in the pathophysiology of the disease, researchers say. Medscape Medical News
Category:   Articles > Allergy and Clinical Immunology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS